

PRESS RELEASE
Uppsala
October 17, 2007

Q-Med AB: Invitation to interim report conference call

Time: Tuesday, October 23, 2007 at 10.00 a.m. CET.

To join the conference

Sweden: +46 (0)8 505 201 10

UK: +44 (0)20 7162 0025

Password: Q-Med

Q-Med participants:

Bengt Ågerup, CEO

Erika Kjellberg Eriksson, CFO

Madelene Sandgren, Director IR and Corporate Communications

The press release for Q-Med AB's interim report will be issued around 8.00 a.m. CET October 23.

The slide presentation will be available at www.q-med.com/Investors/Presentations

A recorded version of the presentation will be available for seven working days on Sweden: +46 (0)8 505 203 33, UK: +44 (0)20 7031 4064, access code: 77 06 44.

Queries should be addressed to:

Madelene Sandgren, Director Investor Relations and Corporate Communications

Tel: +46 (0)70 974 9015

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, MACROLANE for body contouring, DUROLANE for the treatment of osteoarthritis of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA, for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 600 co-workers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap segment of the OMX Nordic Exchange in Stockholm.

NASHA, MACROLANE, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within the RESTYLANE family are trademarks that belong to Q-Med AB.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web: www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.